Panomics Integration via Machine Learning Prioritizes TAF1D as a Therapeutic Vulnerability in Lung Adenocarcinoma

Lan Ding1,2, Qingmei Xu3, Dongdong Liu1

  • 1Department of Thoracic Surgery, Cancer Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China, hznu.edu.cn.

Human Mutation
|April 13, 2026
PubMed

Insights

This study identified a seven-gene signature for lung adenocarcinoma (LUAD) diagnosis. The gene TAF1D was found to be a key driver, promoting cancer growth and suggesting potential for new diagnostics and therapies.

Area of Science:

  • Oncology
  • Genomics
  • Bioinformatics

Background:

  • Lung adenocarcinoma (LUAD) is a major cause of cancer death.
  • Identifying reliable biomarkers and understanding LUAD's molecular basis are crucial.

Purpose of the Study:

  • Screen for potential LUAD biomarkers.
  • Characterize the biological functions of identified biomarkers.

Main Methods:

  • Integrated multitranscriptomic data analysis.
  • Employed machine learning algorithms: LASSO, SVM-RFE, and random forest.
  • Identified a consensus seven-gene signature.

Main Results:

  • A seven-gene signature (TTC13, TAF1D, ZNF587, PRPF3, LINC01355, TARBP1, CCNL2) showed high diagnostic accuracy (AUC = 0.972).
  • TAF1D was the most significant predictor, upregulated in tumors and linked to an immunosuppressive microenvironment.
  • TAF1D influences cancer cell proliferation via cell cycle and immune pathways, with notable spatial heterogeneity.

Conclusions:

  • A validated gene signature for LUAD diagnosis was established.
  • TAF1D is identified as a critical oncogenic driver.
  • TAF1D presents a promising candidate for LUAD diagnostic and therapeutic strategies.